Tibsovo® (ivosidenib) – Expanded indication
May 25, 2022 - Servier Pharmaceuticals announced the FDA approval of Tibsovo (ivosidenib), in combination with azacitidine or as monotherapy for the treatment of newly diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
Top